چاپ صفحه |  صفحه نخست سامانه |  چکیده مقاله |  نویسندگان |  دانلود مقاله | دانشگاه علوم پزشکی تبریز |
| Recurrent implantation failure (RIF), as a challenging problem in human reproduction, is widely improved by intravenous immunoglobulin (IVIG), especially in patients with immunologic abnormalities. In this meta-ana- lysis, we evaluated the results of the studies in which RIF women were treated with IVIG, and pregnancy, live birth, miscarriage and implantation rate were assessed as the result of treatment. A systematic search was conducted in MEDLINE (PubMed), Embase, Cochrane Library, Google Scholar, ProQuest and clinicaltrail.gov. Two cohorts, two cross-sectional and one quasi experimental studies were included in this study. Four out of five studies were included in meta-analysis and remained one study was narratively discussed. Data analysis was conducted by RevMan 5.2 software. Our meta-analysis results demonstrated that there was a significant dif- ference in the pregnancy rate of cohorts (OR=1.82, 95% CI=1.14–2.89, P=0.01) and cross-sectional studies (OR=11.12, 95% CI=6.43–19.23, P < 0.00001), live birth rate of cohorts (OR=2.17, 95% CI=1.30–3.61, P=0.003) and cross-sectional studies (OR=7.57, 95% CI=4.53–12.64, P < 0.00001) in the IVIG group when compared to the control group, but there was no significant difference in the miscarriage rate. In con- clusion, IVIG may be a beneficial therapeutic strategy in RIF patients selected according to relevant im- munological disturbances. However, final conclusions on the efficiency of the treatment must await prospective, randomized controlled trials of sufficient size |
| نویسنده | نفر چندم مقاله |
|---|---|
| مهدی یوسفی | ششم |
| سمانه عبدالمحمدی وحید | اول |
| فریبا پاشازاده | دوم |
| زهرا پورمقدم | سوم |
| لیلی عاقبتی | چهارم |
| نام فایل | تاریخ درج فایل | اندازه فایل | دانلود |
|---|---|---|---|
| 1-s2.0-S0165037819300415-main.pdf | 1398/05/28 | 850160 | دانلود |
